| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Stefano Frara, Filippo Maffezzoni, Gherardo Mazziotti, Andrea Giustin. The Modern Criteria for Medical Management of Acromegaly. Progress in molecular biology and translational science. vol 138. 2017-01-09. PMID:26940387. |
acromegaly is an insidious disorder characterized by excess secretion of growth hormone (gh) and elevated circulating levels of insulin-like growth factor-i (igf-i), generally caused by a pituitary adenoma. |
2017-01-09 |
2023-08-13 |
Not clear |
| Stefano Frara, Filippo Maffezzoni, Gherardo Mazziotti, Andrea Giustin. The Modern Criteria for Medical Management of Acromegaly. Progress in molecular biology and translational science. vol 138. 2017-01-09. PMID:26940387. |
authors have proposed a binary definition of cure for acromegaly, where both gh and igf-i are important determinants: the former is more linked to the presence of residual adenomatous tissue, while the latter to the peripheral activity of the disease. |
2017-01-09 |
2023-08-13 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Rosario Pivonell. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary. vol 19. issue 2. 2016-12-23. PMID:26290466. |
in nearly all cases, acromegaly is caused by excess gh from a pituitary adenoma, resulting in elevated circulating levels of gh and, subsequently, igf-1. |
2016-12-23 |
2023-08-13 |
Not clear |
| David B Youn. 6'6" United States Marine Seeks Treatment for Gynecomastia Only to Learn It Is All in His Head. Military medicine. vol 180. issue 12. 2016-12-16. PMID:26633678. |
adults with gh excess (acromegaly) have a 72% increase in mortality compared with the general population, which is reversible with early detection and intervention. |
2016-12-16 |
2023-08-13 |
Not clear |
| Nicoleta Cristina Olarescu, Jens Bollersle. The Impact of Adipose Tissue on Insulin Resistance in Acromegaly. Trends in endocrinology and metabolism: TEM. vol 27. issue 4. 2016-12-13. PMID:26948712. |
acromegaly is a disease characterized by excessive secretion of growth hormone (gh) and insulin-like growth factor i (igf-i). |
2016-12-13 |
2023-08-13 |
Not clear |
| Pouneh K Fazeli, Jonathan G Teoh, Eleanor L Lam, Anu V Gerweck, Tamara L Wexler, Eliza P Teo, Brian M Russell, Ronen Durst, David McCarty, Rory B Weiner, Michael H Picard, Anne Klibanski, Karen K Mille. Effect of growth hormone treatment on diastolic function in patients who have developed growth hormone deficiency after definitive treatment of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 26. 2016-11-11. PMID:26774401. |
although growth hormone (gh) replacement is prescribed for patients with hypopituitarism due to many etiologies, it is not routinely prescribed for patients with gh deficiency (ghd) after cure of acromegaly (acroghd). |
2016-11-11 |
2023-08-13 |
Not clear |
| Wouter W de Herde. The History of Acromegaly. Neuroendocrinology. vol 103. issue 1. 2016-11-09. PMID:25572320. |
the cause of acromegaly could be further determined after the discovery of growth hormone (gh) and insulin-like growth factor i (igf-i) and after demonstrating an association with gh hypersecretion and elevated circulating igf-i. |
2016-11-09 |
2023-08-13 |
Not clear |
| Kim M J A Claessen, Gherardo Mazziotti, Nienke R Biermasz, Andrea Giustin. Bone and Joint Disorders in Acromegaly. Neuroendocrinology. vol 103. issue 1. 2016-11-09. PMID:25633971. |
acromegaly is a chronic, progressive disease caused by a growth hormone (gh)-producing pituitary adenoma, resulting in elevated gh and insulin-like growth factor 1 concentrations. |
2016-11-09 |
2023-08-13 |
Not clear |
| Kim M J A Claessen, Gherardo Mazziotti, Nienke R Biermasz, Andrea Giustin. Bone and Joint Disorders in Acromegaly. Neuroendocrinology. vol 103. issue 1. 2016-11-09. PMID:25633971. |
unfortunately, despite biochemical control, acromegaly patients suffer from a high prevalence of late manifestations of transient gh excess, significantly impairing their quality of life. |
2016-11-09 |
2023-08-13 |
Not clear |
| John McCabe, John Ayuk, Mark Sherloc. Treatment Factors That Influence Mortality in Acromegaly. Neuroendocrinology. vol 103. issue 1. 2016-11-09. PMID:25661647. |
acromegaly is a rare condition characterized by excessive secretion of growth hormone (gh), which is almost always due to a pituitary adenoma. |
2016-11-09 |
2023-08-13 |
Not clear |
| John McCabe, John Ayuk, Mark Sherloc. Treatment Factors That Influence Mortality in Acromegaly. Neuroendocrinology. vol 103. issue 1. 2016-11-09. PMID:25661647. |
this review will focus on the epidemiological data relating to mortality rates in acromegaly, the relationship between acromegaly and malignancy, the role of gh and insulin-like growth factor-i in assessing the risk of future mortality, and the impact of radiotherapy and hypopituitarism on mortality. |
2016-11-09 |
2023-08-13 |
Not clear |
| Susan M Webb, Xavier Badi. Quality of Life in Acromegaly. Neuroendocrinology. vol 103. issue 1. 2016-11-09. PMID:25661974. |
worse qol is associated with the presence of musculoskeletal pain, headache (if only medical therapy, not surgery, has been provided), having required treatment with radiotherapy, being older, of female gender, with a longer disease duration, coexisting diabetes mellitus, a higher bmi or becoming gh deficient after treatment for acromegaly. |
2016-11-09 |
2023-08-13 |
Not clear |
| Philippe Chanso. Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs. Neuroendocrinology. vol 103. issue 1. 2016-11-09. PMID:25677539. |
treatment of acromegaly aims to correct (or prevent) tumor compression of surrounding tissues by excising the disease-causing lesion and reduce growth hormone (gh) and igf-1 levels to normal values. |
2016-11-09 |
2023-08-13 |
Not clear |
| Jakob Dal, Edward O List, Jens Otto L Jørgensen, Darlene E Berryma. Glucose and Fat Metabolism in Acromegaly: From Mice Models to Patient Care. Neuroendocrinology. vol 103. issue 1. 2016-11-09. PMID:25925240. |
the interplay between animal research and clinical studies has proven useful in the field of acromegaly and should be continued in order to understand the metabolic actions of gh. |
2016-11-09 |
2023-08-13 |
mouse |
| Liliya Rostomyan, Adrian F Daly, Albert Becker. Pituitary gigantism: Causes and clinical characteristics. Annales d'endocrinologie. vol 76. issue 6. 2016-09-30. PMID:26585365. |
acromegaly and pituitary gigantism are very rare conditions resulting from excessive secretion of growth hormone (gh), usually by a pituitary adenoma. |
2016-09-30 |
2023-08-13 |
Not clear |
| Tirissa J Reid, Zhezhen Jin, Wei Shen, Carlos M Reyes-Vidal, Jean Carlos Fernandez, Jeffrey N Bruce, Jane Kostadinov, Kalmon D Post, Pamela U Fred. IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition. Pituitary. vol 18. issue 6. 2016-09-20. PMID:25907335. |
activity of acromegaly is gauged by levels of gh and igf-1 and epidemiological studies demonstrate that their normalization reduces acromegaly's excess mortality rate. |
2016-09-20 |
2023-08-13 |
Not clear |
| Juan F Martín-Rodríguez, Jose L Muñoz-Bravo, Alejandro Ibañez-Costa, Laura Fernandez-Maza, Marcin Balcerzyk, Rocío Leal-Campanario, Raúl M Luque, Justo P Castaño, Eva Venegas-Moreno, Alfonso Soto-Moreno, Alfonso Leal-Cerro, David A Can. Molecular Characterization of Growth Hormone-producing Tumors in the GC Rat Model of Acromegaly. Scientific reports. vol 5. 2016-09-09. PMID:26549306. |
acromegaly is a disorder resulting from excessive production of growth hormone (gh) and consequent increase of insulin-like growth factor 1 (igf-i), most frequently caused by pituitary adenomas. |
2016-09-09 |
2023-08-13 |
human |
| Federico Gatto, Nienke R Biermasz, Richard A Feelders, Johan M Kros, Fadime Dogan, Aart-Jan van der Lely, Sebastian J C M M Neggers, Steven W J Lamberts, Alberto M Pereira, Diego Ferone, Leo J Hoflan. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. European journal of endocrinology. vol 174. issue 5. 2016-08-09. PMID:26888629. |
the high expression of somatostatin receptor subtype 2 (sstr2 also known as sst2) usually present in growth hormone (gh)-secreting adenomas is the rationale for therapy with somatostatin analogs (ssas) in acromegaly. |
2016-08-09 |
2023-08-13 |
Not clear |
| Maria Fleseriu, Andrew R Hoffman, Laurence Katznelso. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: MANAGEMENT OF ACROMEGALY PATIENTS: WHAT IS THE ROLE OF PRE-OPERATIVE MEDICAL THERAPY? Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 21. issue 6. 2016-08-05. PMID:26135961. |
acromegaly is a complex disease characterized by growth hormone (gh) excess originating in most cases from a pituitary tumor. |
2016-08-05 |
2023-08-13 |
Not clear |
| Michael H Shani. LIMITATIONS OF CURRENT APPROACHES FOR THE TREATMENT OF ACROMEGALY. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 22. issue 2. 2016-07-29. PMID:26437214. |
acromegaly is a rare disease characterized by hypersecretion of growth hormone (gh), typically from a benign pituitary somatotroph adenoma, that leads to subsequent hypersecretion of insulin-like growth factor 1 (igf-1). |
2016-07-29 |
2023-08-13 |
Not clear |